Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Is It Time to Implement Adjuvant Targeted Therapy in EGFR-Mutant Non-Small-Cell Lung Cancer?

JCO precision oncology - 1 Jan 2021

Kulkarni Amit A, Naqash Abdul Rafeh, Puri Sonam, Dienstmann Rodrigo

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Chemotherapy, Adjuvant
Share to ErbB Receptors
Share to Lung Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 34109281
DOI: 10.1200/PO.20.00460
PMCID: PMC8177880

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Is It Time to Implement Adjuvant Targeted Therapy in EGFR-Mutant Non-Small-Cell Lung Cancer?PMID 34109281Read ↗

Adjuvant Targeted Therapy for Patients With Epidermal Growth Factor Receptor-Mutant Lung Cancer.Semantic proximity Read ↗

Is there a role for first generation TKIs in adjuvant setting of EGFR mutated early NSCLC?Semantic proximity Read ↗

Adjuvant therapy in non-small cell lung cancer: is targeted therapy joining the standard of care?Semantic proximity Read ↗

Updates in the Management of EGFR-Mutated Non-small Cell Lung Cancer (NSCLC).Semantic proximity Read ↗

Adjuvant Treatment with Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor mutated Non-Small-Cell Lung Carcinoma Patients, Past, Present and FutureSemantic proximity Read ↗

Neoadjuvant immunochemotherapy vs. neoadjuvant targeted therapy plus chemotherapy for EGFR-mutated non-small cell lung cancer: a retrospective study.Semantic proximity Read ↗

Efficacy and safety of adjuvant EGFR-TKIs for non-small cell lung cancer with EGFR mutations after surgery: an updated meta-analysisSemantic proximity Read ↗

[I. What is the Standard Treatment of EGFR-TKIs? Did EGFR-TKIs Improve Treatment for Non-Small Cell Lung Cancer?].Semantic proximity Read ↗

Perioperative Treatment in EGFR-Mutant Early-Stage Non-Small Cell Lung Cancer: Current Evidence and Future Perspectives.Semantic proximity Read ↗

Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects.Semantic proximity Read ↗

Targeted Therapy in Early Stage Non-small Cell Lung Cancer.Semantic proximity Read ↗

Eventual role of EGFR-tyrosine kinase inhibitors in early-stage non-small-cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.